Key result
Clopidogrel in combination with ASA reduced the relative risk of cardiovascular death, MI, or stroke by 20% and the absolute risk by 2.1% compared to standard therapy.
Why the study?
Does dual antiplatelet therapy with clopidogrel and ASA reduce the risk of cardiovascular death, MI, or stroke in patients with acute coronary syndromes or undergoing PCI?
Does dual antiplatelet therapy with clopidogrel and ASA reduce the risk of cardiovascular death, MI, or stroke in patients with acute coronary syndromes or undergoing PCI?
Dual antiplatelet therapy with clopidogrel and ASA significantly reduces atherothrombotic events in patients with acute coronary syndromes and those undergoing PCI, with potential implications for broader stroke prevention.
Answers are grounded in this paper and cite their sources.
Supports DAPT with clopidogrel plus ASA in ACS/PCI; leaves open optimal duration and stroke prevention applications.
Dual antiplatelet therapy that inhibits more than one pathway of platelet activation is appealing and biologically rational. The CURE study evaluated the efficacy and safety of clopidogrel on top of acetylsalicylic acid (ASA) versus standard therapy (including ASA) in over 12,000 patients with unstable angina or non-ST-segment elevation myocardial infarction (MI). Clopidogrel in combination with ASA reduced the relative risk of the combined atherothrombotic endpoint of cardiovascular death, MI or stroke by 20% (95% CI 0.72-0.90; p < 0.001) and the absolute risk of this composite endpoint by 2.1%. While the study was not powered or designed to demonstrate a reduction in stroke, there was a 14% reduction in stroke risk (p > 0.05). Dual antiplatelet therapy was associated with an acceptable 1% increase in the incidence of major bleeding events (p = 0.001). PCI-CURE, a prespecified substudy of patients who underwent percutaneous coronary intervention (PCI) during CURE, confirmed the early and sustained benefits of clopidogrel therapy seen in the overall CURE study. CREDO was a randomized, double-blind, placebo-controlled trial in more than 2,100 patients that evaluated the continuation of clopidogrel on top of standard therapy including ASA for 12 months after PCI, and the benefit of a preprocedural clopidogrel loading dose. The long-term results at 1 year showed that there was a 27% reduction in the risk of stroke, MI or death with long-term clopidogrel therapy (p = 0.02). There was a consistent benefit of extended clopidogrel therapy for each component of the composite endpoint, with a 25.1% relative risk reduction for all-cause stroke. In patients who received clopidogrel > or =6 h before PCI, there was a 39% reduction in the risk of death, MI or urgent target-vessel revascularization at 28 days (p = 0.051). These data suggest important implications in the future for the use of an early loading dose of clopidogrel in patients undergoing carotid stenting and, if proven in current or future trials, the use of a loading dose followed by long-term continuation of clopidogrel in other high-risk atherothrombotic patients such as those with transient ischaemic attack or ischaemic stroke.
No takes yet. Share an insight, caveat, or question.
Philip Teal (2004) conducted a review in Unstable angina, non-ST-segment elevation myocardial infarction (MI), and percutaneous coronary intervention (PCI). Clopidogrel in combination with acetylsalicylic acid (ASA) vs. Standard therapy including ASA was evaluated on Combined atherothrombotic endpoint of cardiovascular death, MI or stroke (RR 0.80, 95% CI 0.72-0.90, p=<0.001). Clopidogrel in combination with ASA reduced the relative risk of cardiovascular death, MI, or stroke by 20% and the absolute risk by 2.1% compared to standard therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: